Co-inhibitory receptors rapidly re-calibrate the activation threshold of T cells, and we demonstrate how anti-PD1 leads to a strong TCR signal strength signature that is a correlate for survival of melanoma patients on anti-PD1 monotherapy. This evidence concerns the gene PDCD1 and melanoma.